Skip to main content

Table 3 Limb and bulbar form of ALS, biomarker levels

From: Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis

 

Group

p

Post hoc test

Limb onset ALS

Bulbar onset ALS

CG

p (limb vs CG)

p (bulbar vs CG)

Median

Min

Max

Median

Min

Max

Median

Min

Max

Clusterin CSF [μg/l]

2240

843

11,700

2011.5

1155

15,646

1987.5

500

3460

0,098

  

Tau-protein CSF [ng/l]

323.5

78

788

302.5

29

923

177.5

55

574

 < 0.0001

 < 0.0001

0.012

Beta amyloid1-42 CSF [ng/l]

920.5

283

1378

932.5

534.6

1491

918

122

1308

0.959

  

p-tau protein CSF [ng/l]

41.2

16.4

61.6

52.7

27.4

107.1

29

17

66.3

0.002

0.027

0.005

  1. The table summarizes statistical comparisons between patients with limb-onset ALS, bulbar-onset ALS, and a control group. Biomarker levels—specifically, clusterin, tau protein, beta-amyloid 1–42, and p-Tau protein—in cerebrospinal fluid were monitored. Comparisons were conducted using the Kruskal–Wallis test. Significant results were observed in the case of tau protein and p-Tau protein, prompting the execution of post hoc tests with Bonferroni correction. No differences in biomarker levels were found between ALS cases with limb onset and with bulbar onset
  2. ALS, amyotrophic lateral sclerosis; CG, control group; CSF, cerebrospinal fluid
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us